University of California

Immune Modulation, Inc.

Brigham Young University

Other

Howard B Cottam

Dennis A Carson

Lorenzo M Leoni

Emmanuel A Ojo-Amaize

Christina C N Wu

Michael L Chan

Emeka Nchekwube

Wolfgang J Wrasidlo

Roland K Robins

Carlos J Carrera

Tsutomu Nobori

Kenji Takabayashi

Mary Patricia Corr

Tomoko Hayashi

Soichi Adachi

Olusola Oyemade

Lynn Deng

Souchi Adachi

Gregory A Daniels

Ganesh D Kini

Joseph I Okogun

Sylvie Barchéchath

Donna G Nchekwube

Hsien C Shih

Guangyi Jin

D Bruce Wasson

New uses of hypoestoxide, its derivatives and related compounds for treatment and prevention of neurodegenerative diseases (e.g. Parkinsons disease, Alzheimers disease, Huntingtons disease) are described. More specifically, the invention relates to methods for treating various neurodegenerative diseases through administration of hypoestoxide, its derivatives and related compounds, or a combination thereof to a subject with a neurodegenerative disease such that the symptoms of the disease are treated or at least partially alleviated. Furthermore, the present invention further provides methods of preventing the development of neurodegenerative diseases in individuals who are predisposed to developing a neurodegenerative disease over time.

Hypoestoxide, derivatives, related compounds, and agonists thereof for treatment or prevention of neurodegenerative diseases

Provided herein, inter alia, are methods and compositions for modulating TLR-4.

Compositions and methods for modulating TLR4

The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.

TLR agonists

The invention provides TLR agonists and conjugates thereof useful in vaccines and to prevent, inhibit or treat a variety of disorders including pathogen infection and asthma.

Conjugates of synthetic TLR agonists and uses therefor

The present invention provides purine analog compounds, as well as compositions and methods of using them, for example, to prevent or treat various diseases and disorders in human and non-human animals. For example, the invention provides for a compound having formula II: 

Purine analogs

Provided herein are small molecule conjugates that are agonists or antagonists of one or more toll-like receptors. For example, such conjugates include a structure according to Formula I: 

Toll-like receptor modulators and treatment of diseases

Novel diterpene compounds, in particular, hypoestoxide-related compounds, are provided in pure form or as contained in the native plant source, for treatment and prophylaxis of cancer, inflammatory diseases, hyperlipidemias, malaria, and diabetes mellitus. Embodiments also pertain to methods for using the hypoestoxide-related compounds to treat various diseases and symptoms associated with those diseases.

Derivatives of hypoestoxide and related compounds

The present invention provides compounds that act as selective agents to protect against unintentional cell death or tissue damage and can relieve side effects of cancer treatment such as, for example, oral mucositis, hair loss, diarrhea due to damage to the gastrointestinal epithelium, and myelosuppression. In addition, these compounds can be used to prevent premature cell death when the cell death is caused by signals from damaged cells, for example, signals generated as the result of a traumatic incident or an ischemic episode.

Apoptosis inhibitors

The present invention provides compounds that can protect mammalian cells from the damaging effects of chemotherapy, irradiation, or in other situations in which it is desirable to protect tissue from the consequences of clinical or environmental stress.

Compounds having activity as inhibitors of apoptosis

The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments.

Indole compounds useful for the treatment of cancer

Methods of treating a host suffering from restenosis are provided. The methods include delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The methods further include the administration of a chemotherapeutic agent in combination with delivery of a stent coated with a hypoestoxide, hypoestoxide derivative or hypoestoxide agonist compound to a vessel. The chemotherapeutic agent may be coated on the stent or administered systemically.

Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents

A method of treating cancer is provided comprising administering an amount of etodolac or analog theteof to a subject afflicted with leukemia that is effective to reduce the viability and/or to sensitize leukemia cells to an anti-cancer agent.

Growing community of inventors

Fallbrook, CA, United States of America

Howard B Cottam